This site is intended for healthcare professionals
Abstract digital waveforms in blue and purple
FDA Drug information

Triazolam

Read time: 1 mins
Marketing start date: 23 Dec 2024
...
 

Summary of product characteristics


Effective Time

20230928

Version

2

Spl Product Data Elements

Triazolam Triazolam TRIAZOLAM TRIAZOLAM D&C RED NO. 27 FD&C BLUE NO. 1 LACTOSE MONOHYDRATE MAGNESIUM STEARATE MICROCRYSTALLINE CELLULOSE POVIDONE SILICON DIOXIDE SODIUM LAURYL SULFATE STARCH, CORN light-grayish blue elliptical 12;89 Triazolam Triazolam TRIAZOLAM TRIAZOLAM LACTOSE MONOHYDRATE MAGNESIUM STEARATE MICROCRYSTALLINE CELLULOSE POVIDONE SILICON DIOXIDE SODIUM LAURYL SULFATE STARCH, CORN off-white elliptical 1521

Application Number

ANDA213003

Brand Name

Triazolam

Generic Name

Triazolam

Product Ndc

70771-1162

Product Type

HUMAN PRESCRIPTION DRUG

Route

ORAL

Package Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 70771-1576-8 Triazolam Tablets USP, 0.125 mg 10 Tablets Rx only NDC 70771-1162- 8 Triazolam Tablets USP, 0.25 mg 10 Tablets Rx only 0.125 mg label 0.25 mg label

Spl Medguide

SPL MEDGUIDE

Drug section

CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.